Chronic myeloid leukemia
Onkologe, ISSN: 1433-0415, Vol: 24, Issue: 5, Page: 427-442
2018
- 3Citations
- 90Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Article Description
The advent of tyrosine kinase inhibitors (TKI) imatinib has considerably improved prognosis of patients with chronic myeloid leukemia (CML). In comparison to imatinib, first-line use of second-generation inhibitors nilotinib, dasatinib, and bosutinib has led to faster and deeper molecular remissions accompanied by a novel adverse event profile. Long-lasting treatment-free remission in an important minority of patients prompted the hope for curability of CML. An essential part of the management of CML patients is consequent cytogenetic and molecular follow-up with standardized methods to regularly assess the remission status. The use of interferon-α in parallel with or after TKI therapy is associated with the induction of an immune response against the leukemic clone with further improvement of the remission rate. A novel allosteric kinase inhibitor (asciminib) could further improve treatment of CML patients in the near future.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85045831210&origin=inward; http://dx.doi.org/10.1007/s00761-018-0380-5; http://link.springer.com/10.1007/s00761-018-0380-5; http://link.springer.com/content/pdf/10.1007/s00761-018-0380-5.pdf; http://link.springer.com/article/10.1007/s00761-018-0380-5/fulltext.html; https://dx.doi.org/10.1007/s00761-018-0380-5; https://link.springer.com/article/10.1007/s00761-018-0380-5
Springer Nature
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know